Synonyms: CTP-543 | CTP543 | D8-ruxolitinib | Leqselvi®
deuruxolitinib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Deuruxolitinib (CTP-543) is a deuterium-modified analogue of the JAK inhibitor ruxolitinib. It is an oral inhibitor that inhibits JAK1/2. The chemical structure, and its use in hair loss disorders are claimed in patent WO2017192905A1 [3].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2024)) |
IUPAC Name ![]() |
(3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
International Nonproprietary Names ![]() |
|
INN number | INN |
11622 | deuruxolitinib |
Synonyms ![]() |
CTP-543 | CTP543 | D8-ruxolitinib | Leqselvi® |
Database Links ![]() |
|
CAS Registry No. | 1513883-39-0 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4594381 |
GtoPdb PubChem SID | 440816779 |
PubChem CID | 72704611 |
Search Google for chemical match using the InChIKey | HFNKQEVNSGCOJV-FBXGHSCESA-N |
Search Google for chemicals with the same backbone | HFNKQEVNSGCOJV |
Search PubMed clinical trials | deuruxolitinib |
Search PubMed titles | deuruxolitinib |
Search PubMed titles/abstracts | deuruxolitinib |
UniChem Compound Search for chemical match using the InChIKey | HFNKQEVNSGCOJV-FBXGHSCESA-N |
UniChem Connectivity Search for chemical match using the InChIKey | HFNKQEVNSGCOJV-FBXGHSCESA-N |